GSK counters TV report on Cidra plant

GlaxoSmithKline ($GSK) wasn't amused by the 60 Minutes feature on whistleblower Cheryl Eckard, whose allegations against the company led to a $750 million settlement with the U.S. Justice Department. The drugmaker issued a statement rebutting some implications in the report, namely that patients might have been hurt by medication mix-ups at its now-closed plant in Cidra, Puerto Rico. "GSK strongly disagrees" with the implication that patients were harmed, the statement says.

"The FDA; the U.S. Department of Justice; and Neil Getnick, Cheryl Eckard's attorney, all stated there was no indication that" production problems at Cidra hurt anyone, the statement says. Plus, U.S. Attorney Carmen Ortiz, in announcing last year's $750 million settlement of charges that GSK distributed adulterated meds, noted that her office had found no evidence that patients were hurt.

The company also took issue with the suggestion that it retaliated against Eckard after she lambasted conditions at the Cidra plant. GSK workers are "encouraged" to report their concerns to management or to a confidential compliance hotline, the statement explains. "Issues raised are investigated, and company policy prohibits any retaliation against employees."

- see the GSK statement
- read the in-Pharma Technologist story
- get more from WRAL-TV

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.